Global ELISpot and FluoroSpot Assay Market, By Product Type (Assay Kits, Analysers, Supplementary Or Ancillary Products), By Source (Human, Mouse, Monkey And Others), Diseases (Infectious Diseases, Cancer, Autoimmune Diseases, Allergy And Others), Application (Diagnostic Applications, Research Applications,), End User (Hospitals and Clinical Laboratories, Research Institutes, Biopharmaceutical Companies And Others), Distribution (Direct Tender, Retail Sales) – Industry Trends and Forecast to 2031.
ELISpot and FluoroSpot Assay Market Analysis and Size
The enzyme-linked immunospot (ELISpot) assay, known for its high sensitivity, is extensively employed for diagnosing diverse diseases. Its flexibility is evident in measuring antigen-specific T cells in both mice and humans. Increasingly popular, ELISpot is preferred for its ability to assess a broad spectrum of immune responses and cellular activities. This transformation has propelled ELISpot from a research tool to a widely adopted clinical assay, prominently utilized in laboratories for comprehensive disease diagnostics.
Data Bridge Market Research analyses that the global ELISpot and FluoroSpot assay market which was USD 301.25 million in 2023, is expected to reach USD 784.00 million by 2031, and is expected to undergo a CAGR of 12.7% during the forecast period of 2024 to 2031.This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
ELISpot and FluoroSpot Assay Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Assay Kits, Analysers, Supplementary Or Ancillary Products), By Source (Human, Mouse, Monkey And Others), Diseases (Infectious Diseases, Cancer, Autoimmune Diseases, Allergy And Others), Application (Diagnostic Applications, Research Applications,), End User (Hospitals and Clinical Laboratories, Research Institutes, Biopharmaceutical Companies And Others), Distribution (Direct Tender, Retail Sales)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Oxford Immunotec USA, Inc.(U.S.), BD (U.S.), R&D Systems, Inc.(U.S.), Mabtech (Sweden), Thermo Fischer Scientific (U.S.), Covalab, Inc. (France), Oxford BioSystems (U.K.), AUTOIMMUN DIAGNOSTIKA GMBH (Germany), Abcam Limited (U.K.), Labcorp Drug Development (U.S.), Cellular Technology Limited (U.S.), U-CyTech (Netherlands) Bio-Techne (U.S.), MIKROGEN GmbH. (Germany)
|
|
Market Opportunities
|
|
Market Definition
Enzyme-linked immunospot (ELISpot) and FluoroSpot assays are immunological techniques used to quantify specific immune responses at the single-cell level. ELISpot detects secreted proteins, typically cytokines, from individual cells, providing insight into cellular immune activity. FluoroSpot extends this by incorporating fluorescent detection, allowing simultaneous assessment of multiple analytes. These assays are crucial in immunology research and clinical diagnostics, aiding in understanding and monitoring immune responses.
Global ELISpot and FluoroSpot Assay Market Dynamics
Drivers
- Increasing prevalence of chronic diseases
The ELISpot and FluoroSpot assays, offering precise quantification at the single-cell level, are instrumental in disease diagnosis, treatment monitoring, and vaccine development. With a surge in global chronic diseases, these immunological assays have become crucial for understanding and monitoring immune responses linked to chronic conditions. As a result, the healthcare sector experiences growing demand for these technologies, marking them as essential tools in advancing medical research and diagnostics.
- Rising demand in disease diagnostics
The ELISpot and FluoroSpot assay market is propelled by a rising demand for accurate diagnostics in infectious diseases, autoimmune disorders, and cancer. These assays offer single-cell level insights into immune responses, enabling clinicians and researchers to diagnose and monitor diseases with precision. As the importance of personalized and targeted therapies grows, the market for ELISpot and FluoroSpot assays continues to expand to meet the evolving requirements of disease diagnostics.
Opportunities
- Rise in immunology research
The escalating research focus in immunology, spanning infectious diseases, cancer, and autoimmune disorders, presents a significant opportunity for the ELISpot and FluoroSpot assay market. As these assays play a pivotal role in understanding immune responses, the surge in immunology research acts as a catalyst, driving increased demand and adoption in both research and clinical applications.
- Expanding applications
The diverse applications of ELISpot and FluoroSpot assays, ranging from vaccine development to monitoring treatment effectiveness and personalized medicine, present a significant opportunity for market expansion. As these assays prove instrumental across various medical domains, their versatile utility positions them as crucial tools for advancing research and diagnostics in healthcare.
Restraints/Challenges
- High costs
High costs associated with initial setup and reagent expenses create a significant barrier to the widespread adoption of ELISpot and FluoroSpot assays, particularly in resource-constrained settings. This financial constraint limits accessibility and hampers the market's growth, impeding the integration of these valuable immunological techniques in diverse research and diagnostic applications.
- Skill-Dependent Technique
The ELISpot and FluoroSpot assays are challenged by their skill-dependent nature, demanding specialized expertise for accurate execution. This dependence on skilled personnel may hinder the broader adoption of these assays, limiting accessibility and potentially impacting the consistency and reliability of results across diverse laboratory settings.
This global ELISpot and FluoroSpot assay market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global ELISpot and FluoroSpot assay market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In June 2022, BD and CerTest Biotec joined forces to develop a molecular diagnostic test for Monkeypox virus, a rare ailment linked to smallpox. Utilizing BD MAX open system reagents, the collaboration validates CerTest VIASURE Monkeypox CE/IVD molecular test on the BD MAX System. This aims to enhance Monkeypox diagnosis, management, and contribute to global disease spread insights
- In April 2022, ProImmune Ltd. introduced a B-cell ELISpot assay service, a method for analyzing B cell immune responses crucial for defense against infections and therapeutic interventions. Researchers can gauge vaccine efficacy or drug potency by quantifying B cells producing specific antibodies in response to stimuli, enhancing assessments of immunological interventions
- In April 2021, BD's participation in virtual investor healthcare conferences, including "The Bank of America Securities 2021 Virtual Healthcare Conference" and "The UBS Global Healthcare Virtual Conference," facilitated global visibility. This strategic engagement likely attracted new customers and contributed to enhanced future market revenue for the company
Global ELISpot and FluoroSpot Assay Market Scope
The global ELISpot and FluoroSpot assay market is segmented on the basis of product type, source, diseases, applications, end user and distribution. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Assay Kits
- Analysers
- Supplementary or Ancillary Products
Source
- Human
- Mouse
- Monkey
- Others
Diseases
- Infectious Diseases
- Cancer
- Autoimmune Diseases
- Allergy
- Others
Application
- Diagnostic Applications
- Research Applications
End User
- Hospitals and Clinical Laboratories
- Research Institutes
- Biopharmaceutical Companies
- Others
Distribution
- Direct Tender
- Retail Sales
Global ELISpot and FluoroSpot Assay Market Regional Analysis/Insights
The global ELISpot and FluoroSpot assay market is analysed and market size insights and trends are provided by country product type, source, diseases, applications, end user and distribution as referenced above.
The countries covered in the global ELISpot and FluoroSpot assay market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the ELISpot and FluoroSpot assay market, driven by its largest consumer market, high GDP, and increased technological advancements. The region's prominence is further accentuated by the rise of infectious chronic diseases and the presence of major market players, solidifying its leadership in advancing immunological research and diagnostics.
Asia-Pacific is expected to witness significant growth in the ELISpot and FluoroSpot assay market from 2024 to 2031. This surge is driven by the rise in immunology research, advancements in technology, expanding applications, and the growth of the biopharmaceutical industry, reflecting the region's increasing prominence in driving advancements in immunological assays.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The global ELISpot and FluoroSpot assay market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global ELISpot and FluoroSpot assay market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global ELISpot and FluoroSpot assay market. The data is available for historic period 2016-2021.
Competitive Landscape and Global ELISpot and FluoroSpot Assay Market Share Analysis
The global ELISpot and FluoroSpot assay market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global ELISpot and FluoroSpot assay market.
Some of the major players operating in the global ELISpot and FluoroSpot assay market are:
- Oxford Immunotec USA, Inc.(U.S.)
- BD (U.S.)
- R&D Systems, Inc. (U.S.)
- Mabtech (Sweden)
- Thermo Fischer Scientific (U.S.)
- Covalab, Inc. (France)
- Oxford BioSystems (U.K.)
- AUTOIMMUN DIAGNOSTIKA GMBH (Germany)
- Abcam Limited (U.K.)
- Labcorp Drug Development (U.S.)
- Cellular Technology Limited (U.S.)
- U-CyTech (Netherlands)
- Bio-Techne (U.S.)
- MIKROGEN GmbH. (Germany)
SKU-